Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Hyperlipidemia Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Hyperlipidemia Overview | 14 | 1 |
| Pipeline Products for Hyperlipidemia Comparative Analysis | 15 | 1 |
| Hyperlipidemia Therapeutics under Development by Companies | 16 | 4 |
| Hyperlipidemia Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Hyperlipidemia Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Hyperlipidemia Products under Development by Companies | 25 | 3 |
| Hyperlipidemia Products under Investigation by Universities/Institutes | 28 | 1 |
| Hyperlipidemia Companies Involved in Therapeutics Development | 29 | 36 |
| Acasti Pharma Inc. | 29 | 1 |
| Akcea Therapeutics Inc | 30 | 1 |
| Allergan Plc | 31 | 1 |
| Alnylam Pharmaceuticals, Inc. | 32 | 1 |
| Amgen Inc. | 33 | 1 |
| Arisaph Pharmaceuticals, Inc. | 34 | 1 |
| AstraZeneca Plc | 35 | 1 |
| BASF SE | 36 | 1 |
| BCWorld Pharm Co. Ltd. | 37 | 1 |
| BioRestorative Therapies, Inc. | 38 | 1 |
| Cadila Pharmaceuticals Limited | 39 | 1 |
| Cardax Pharmaceuticals, Inc. | 40 | 1 |
| Catabasis Pharmaceuticals, Inc. | 41 | 1 |
| CJ HealthCare Corp. | 42 | 1 |
| CymaBay Therapeutics, Inc. | 43 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 44 | 1 |
| Esperion Therapeutics, Inc. | 45 | 1 |
| Golden Biotechnology Corp. | 46 | 1 |
| HanAll Biopharma Co., Ltd. | 47 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 48 | 1 |
| Huons Co., Ltd. | 49 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 50 | 1 |
| Innovent Biologics, Inc. | 51 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 52 | 1 |
| Kowa Company, Ltd. | 53 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 54 | 1 |
| LG Life Science LTD. | 55 | 1 |
| LipimetiX Development Inc | 56 | 1 |
| Matinas BioPharma Holdings, Inc. | 57 | 1 |
| Pfizer Inc. | 58 | 1 |
| Pharmena SA | 59 | 1 |
| Protalix BioTherapeutics, Inc. | 60 | 1 |
| Regeneron Pharmaceuticals Inc | 61 | 1 |
| Sancilio &Company, Inc. | 62 | 1 |
| Yuhan Corporation | 63 | 1 |
| Zydus Cadila Healthcare Limited | 64 | 1 |
| Hyperlipidemia Therapeutics Assessment | 65 | 14 |
| Assessment by Monotherapy Products | 65 | 1 |
| Assessment by Combination Products | 66 | 1 |
| Assessment by Target | 67 | 4 |
| Assessment by Mechanism of Action | 71 | 4 |
| Assessment by Route of Administration | 75 | 2 |
| Assessment by Molecule Type | 77 | 2 |
| Drug Profiles | 79 | 107 |
| (amlodipine besylate + atorvastatin calcium + valsartan) Drug Profile | 79 | 1 |
| (amlodipine besylate + rosuvastatin calcium + valsartan) Drug Profile | 80 | 1 |
| (atorvastatin calcium + losartan potassium) Drug Profile | 81 | 1 |
| (atorvastatin calcium + metformin hydrochloride) XR Drug Profile | 82 | 1 |
| (ezetimibe + rosuvastatin calcium) Drug Profile | 83 | 1 |
| (gemigliptin + rosuvastatin calcium) Drug Profile | 84 | 1 |
| (metformin hydrochloride SR + rosuvastatin calcium) Drug Profile | 85 | 1 |
| AC-261066 Drug Profile | 86 | 1 |
| AEM-28 Drug Profile | 87 | 2 |
| AEM-2802 Drug Profile | 89 | 1 |
| AEM-2814 Drug Profile | 90 | 1 |
| ALN-AC3 Drug Profile | 91 | 1 |
| ALN-ANG Drug Profile | 92 | 1 |
| antroquinonol Drug Profile | 93 | 2 |
| ARI-3037MO Drug Profile | 95 | 2 |
| BCWPC-001 Drug Profile | 97 | 1 |
| bempedoic acid Drug Profile | 98 | 8 |
| bezafibrate ER Drug Profile | 106 | 1 |
| BH-03004 Drug Profile | 107 | 1 |
| BioE-1115 Drug Profile | 108 | 1 |
| bococizumab Drug Profile | 109 | 4 |
| BSN-272 Drug Profile | 113 | 1 |
| CAT-2000 Series Drug Profile | 114 | 1 |
| CAT-2003 Drug Profile | 115 | 3 |
| CDX-085 Drug Profile | 118 | 2 |
| centatin Drug Profile | 120 | 1 |
| DWJ-1351 Drug Profile | 121 | 1 |
| etanercept biosimilar Drug Profile | 122 | 2 |
| evolocumab Drug Profile | 124 | 12 |
| gemcabene calcium Drug Profile | 136 | 2 |
| HOB-071 Drug Profile | 138 | 1 |
| HU-012 Drug Profile | 139 | 1 |
| IBI-306 Drug Profile | 140 | 1 |
| icosabutate Drug Profile | 141 | 1 |
| IMMH-007 Drug Profile | 142 | 1 |
| ISIS-APOCIIILRx Drug Profile | 143 | 1 |
| JS-002 Drug Profile | 144 | 1 |
| K-312 Drug Profile | 145 | 1 |
| leucine + niacin Drug Profile | 146 | 1 |
| LTPO-3FA Drug Profile | 147 | 1 |
| MAT-9001 Drug Profile | 148 | 2 |
| MBX-8025 Drug Profile | 150 | 3 |
| MN-002 Drug Profile | 153 | 1 |
| NKPL-66 Drug Profile | 154 | 4 |
| Oligonucleotide for Hyperlipidemia and Atherosclerosis Drug Profile | 158 | 1 |
| omega-3-carboxylic acids Drug Profile | 159 | 4 |
| PF-06427878 Drug Profile | 163 | 1 |
| PF-06815345 Drug Profile | 164 | 1 |
| Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia Drug Profile | 165 | 1 |
| REGN-1001 Drug Profile | 166 | 1 |
| saroglitazar Drug Profile | 167 | 2 |
| SC-401 Drug Profile | 169 | 1 |
| Small Molecule for Atherosclerosis and Hyperlipidemia Drug Profile | 170 | 1 |
| Small Molecule for Hyperlipidemia Drug Profile | 171 | 1 |
| Small Molecule for Hypertriglyceridaemia Drug Profile | 172 | 1 |
| Small Molecule for Type 2 Diabetes and Hyperlipidemia Drug Profile | 173 | 1 |
| Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes Drug Profile | 174 | 2 |
| Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease Drug Profile | 176 | 1 |
| TRIA-662 Drug Profile | 177 | 2 |
| volanesorsen sodium Drug Profile | 179 | 6 |
| YH-22189 Drug Profile | 185 | 1 |
| Hyperlipidemia Dormant Projects | 186 | 9 |
| Hyperlipidemia Discontinued Products | 195 | 1 |
| Hyperlipidemia Product Development Milestones | 196 | 12 |
| Featured News &Press Releases | 196 | 1 |
| Jul 11, 2016: Wests SmartDose Drug Delivery Technology Platform Selected by Amgen for Pushtronex System | 196 | 1 |
| Jun 28, 2016: Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid | 196 | 2 |
| Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions | 198 | 1 |
| May 23, 2016: BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders | 198 | 1 |
| May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen | 199 | 1 |
| May 11, 2016: Cigna s New Value-Based Contract with Amgen for Repatha | 199 | 1 |
| May 04, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates | 200 | 2 |
| Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association | 202 | 1 |
| Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association" | 202 | 1 |
| Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab | 203 | 1 |
| Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia | 204 | 1 |
| Mar 21, 2016: Amgen To Present Repatha (Evolocumab) Data At ACC.16 | 205 | 2 |
| Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab) | 207 | 1 |
| Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims | 207 | 1 |
| Feb 04, 2016: Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha (Evolocumab) In Statin-Intolerant Patients With High Cholesterol | 207 | 1 |
| Appendix | 208 | 2 |
| Methodology | 208 | 1 |
| Coverage | 208 | 1 |
| Secondary Research | 208 | 1 |
| Primary Research | 208 | 1 |
| Expert Panel Validation | 208 | 1 |
| Contact Us | 208 | 1 |
| Disclaimer | 209 | 1 |